Biotech Deal Toys

Custom Lucite commemorating a development and commercialization agreement between Japanese drug maker Takeda and California-based Arrowhead Pharmaceuticals. The agreement centers on drugs that treat disease by using RNA to block gene expression. (21ALJ357)

Lucite commemorative celebrating a development and commercialization agreement between Takeda and Arrowhead Pharmaceuticals. (21ALJ357)

Back view of crystal tombstone commemorating a senior bond offering by Siegfried Holding. Based in Switzerland, the life sciences company provides both primary and secondary drug manufacturing. (21LSS233)

Financial tombstone marking the successful placement by Siegfried Holding of a senior bond. The Swiss firm provides development and production services to the pharmaceutical and life sciences sectors. (21LSS233)

Back view of custom financial tombstone recognizing a public offering by electroCore. The commercial-stage bioelectric medicine firm is based in Basking Ridge, New Jersey. (21AJH117)

Side view of deal tombstone marking a follow-0n offering by New Jersey-based electroCore. (21AJH117)

Crystal deal toy commemorating a follow-on offering by electroCore, a bioelectronic medicine company. (21AJH117)

Financial tombstone marking a private placement by X4 Pharmaceuticals. (21ALJ247)

Crystal deal toy commemorating a private placement by X4 Pharmaceuticals. (21ALJ247)

Crystal deal tombstone celebrating Series A financing for Interius BioTherapeutics. The gene therapy developer is based in Philadelphia. (21AKL266)

Crystal deal toy commemorating Series A financing for Interius BioTherapeutics,  a preclinical stage gene therapy firm. (21AKL266)

Back view of custom crystal celebrating the initial public offering on the Australia Securities Exchange of Chimeric Therapeutics. (21ALJ210)

Crystal commemorative marking the initial public offering of Australian biotech firm Chimeric Therapeutics. The firm is developing a class of cell therapy drugs for the treatment of cancer. (21ALJ210)

Lucite deal toy marking crossover funding provided to biotech firm AbSci. (21ALJ163)

Lucite tombstone commemorating crossover funding for AbSci, a Vancouver, Washington-based biotech firm. (21ALJ163)

Logo-themed del toy celebrating the listing on the Oslo-based Euronext Growth exchange of Arctic Bioscience. Based in Ørsta, Norway, the biotech firm develops products for pharmaceutical and nutraceutical applications. (21LJW055)

Crystal deal tombstone celebrating the initial public offering of Arctic Bioscience. The Norwegian biotech firm makes use of bioactive marine compounds, including herring roe extracts. (21LJW055)

Custom financial tombstone commemorating an offering by Artelo Biosciences, a San Diego-based biopharmaceutical firm. (20AJH203)

Custom deal toy celebrating a follow-on public offering by Applied UV, a technology company employing narrow-range ultra violet light (UVC) to combat pathogens. (20AJH232)

Lucite tombstone celebrating Series A funding for Trailhead Biosystems. The Cleveland-based biotechnology company is focused on the application of machine-enabled technology. (21ADH001)

Lucite deal toy celebrating a public offering of American Depositary Shares, and concurrent private placement, by Calliditas Therapeutics. The pharmaceutical firm is based in Stockholm, Sweden. (20ALJ348)

Lucite tombstone celebrating a private placement and concurrent global offering of shares by Calliditas Therapeutics. Joint bookrunners in the offering by the Swedish biotech firm were Citi, Jefferies, and Stifel. (20ALJ348)

Crystal deal toy commemorating the acquisition of Philadelphia-based Spark Therapeutics. The acquiring firm, Swiss pharmaceutical firm Roche, is headquartered in Basel. (9ALJ621)

Crystal deal toy, incorporating an interior, 3-D etching of Thor's hammer, commemorating a private placement by pharmaceutical company Photocure ASA. Based in Oslo, Norway, Photocure specializes in photodynamic therapies that make use of light-activated drugs. (20LJW163)

Custom financial tombstone commemorating the ipo of New Zealand-based medicinal cannabis firm Rua Bioscience. (20ALJ334)

Crystal deal toy celebrating the initial public offering by pharmaceutical firm Rua Bioscience. The New Zealand-based company is licensed to produce cannabis-derived medicines. (20ALJ334)

Crystal commemorative marking the submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA). INP104 was developed for the acute treatment of migraine headaches. (20ALJ356)

Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma's migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial. (20ALJ356)

Crystal deal toy commemorating a loan facility provided for Biohaven Pharmaceuticals, based in New Haven, Connecticut. (20ALJ278)

Custom crystal deal toy commemorating a follow-on offering by Windtree Therapeutics. The Pennsylvania-based firm is focused on medical devices and drug therapies for the treatment of pulmonary and cardiovascular diseases. (20AJH070)